# A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

> **NCT00911898** · PHASE1 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Her2 Amplified Solid Tumors
- Metastatic Breast Cancer

## Interventions

- **DRUG:** MM-111

## Key facts

- **NCT ID:** NCT00911898
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911898, "A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00911898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*